BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17302185)

  • 1. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
    Rose-John S; Schooltink H
    Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 and its receptor: from bench to bedside.
    Scheller J; Rose-John S
    Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
    Rose-John S
    Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
    Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
    Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
    Rose-John S
    Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking only the bad side of IL-6 in inflammation and cancer.
    Rose-John S
    Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regenerative activity of interleukin-6.
    Galun E; Rose-John S
    Methods Mol Biol; 2013; 982():59-77. PubMed ID: 23456862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
    Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
    Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
    Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
    Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. sIL-6R: more than an agonist?
    Knüpfer H; Preiss R
    Immunol Cell Biol; 2008 Jan; 86(1):87-91. PubMed ID: 17724457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
    Scheller J; Garbers C; Rose-John S
    Semin Immunol; 2014 Feb; 26(1):2-12. PubMed ID: 24325804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease.
    Schumertl T; Lokau J; Rose-John S; Garbers C
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119143. PubMed ID: 34626681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
    Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
    J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
    Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
    J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.